Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment
First-of-its-Kind Multi-Modal AI Platform Combines Advanced Behavioral Analysis with Claude AI to Accelerate Traumatic Brain Injury Recovery Monitoring, Among Other Medical Applications
JACKSON CENTER, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) today announced its acquisition of NeuroSense AI Corp., a groundbreaking artificial intelligence platform that will revolutionize behavioral analysis for traumatic brain injury (TBI) research and clinical assessment. The proprietary platform represents the first commercial development of multi-modal behavioral signal fusion.
Breaking New Ground in AI-Powered Healthcare
NeuroSense AI will address a critical gap, starting with TBI research, where traditional observational methods often fail to capture subtle neurological changes that precede clinical manifestations. The platform's innovative approach fuses three distinct behavioral data streams – vocal patterns, movement dynamics, and social interactions – through advanced AI algorithms powered by Claude AI technology. Among each of those three data streams are multiple data points, ripe for analysis to better assess deviations from norms that may evidence, for example, toxic buildup of antigens associated with the targeted disease state or affliction.
"NeuroSense AI represents a paradigm shift in how we understand and monitor brain health," commented William Hartman, CEO of Halberd Corporation. "By combining cutting-edge sensor technology with artificial intelligence, we're providing researchers and clinicians with tools that can detect neurological changes weeks or months before traditional methods. Moreover, the degree of such deviations from the norm become more demonstrable and quantifiable. The magnitude of each such deviation, coupled with the greater number of variables/data points to test, will render test results more evident. Presumably, less testing would be required before the requisite level of proof for the FDA is achieved. This could be particularly revolutionary, considering the amount of time required to achieve the appropriate standard of proof of efficacy. We intend to implement this capability into the upcoming Phase 2 animal testing being planned at Mississippi State University."
Proprietary Technology Delivers Clinical-Grade Insights
The NeuroSense AI platform leverages proprietary algorithms to analyze and often quantify:
- Ultrasonic Vocalization Patterns: Advanced audio processing detects stress indicators, frequency variations, and temporal changes in vocal behavior particularly in animal research and testing;
- Micro-Movement Analysis: Computer vision technology tracks subtle changes in grooming, mobility, and spatial behavior patterns;
- Social Dynamic Monitoring: AI-powered assessment of interaction patterns, engagement timing, and social preference indicators.
This multi-modal approach generates comprehensive behavioral fingerprints that enable researchers to track recovery trajectories, assess treatment efficacy, and identify early warning signs of neurological decline with unprecedented accuracy. And, with the multiplicity of data points, test results become far more quantifiable and the results far more evident.
First-Mover Advantage in Billion-Dollar Market
The global behavioral health market is projected to reach $240 billion by 2030, with AI-driven diagnostic tools representing the fastest-growing segment. NeuroSense AI Corp. positions Halberd as the first company to commercialize Claude AI-powered behavioral analysis, providing significant competitive advantages in both research and clinical markets.
"We're not just launching a product – we're creating an entirely new category of AI-powered behavioral intelligence," said the platform's lead developer. "The combination of real-time multi-modal analysis with advanced AI interpretation has never before been achieved in a commercial platform."
Immediate Applications Across Multiple Markets
Research Institutions: Universities and research centers can leverage NeuroSense AI to accelerate TBI studies, improve data quality, and publish breakthrough research with unprecedented behavioral insights.
Clinical Applications: Hospitals and rehabilitation centers gain objective tools for tracking patient progress, optimizing treatment protocols, and providing evidence-based care recommendations. And those tools become far more potent, given the multiple data points, thus facilitating much more quantifiable results.
Pharmaceutical Development: Drug developers can utilize the platform for clinical trials, biomarker discovery, and regulatory submissions with robust behavioral endpoint data.
Government and Military: Defense applications include personnel assessment, injury evaluation, and long-term health monitoring for service members.
Technical Innovation Meets Regulatory Readiness
Halberd’s NeuroSense AI is being implemented to accord with FDA regulatory pathways in mind, featuring comprehensive documentation, validation protocols, and clinical-grade accuracy standards. The platform's cloud-native architecture will ensure scalability from single-subject studies to large multi-site clinical trials.
Key technical capabilities include:
- Real-time behavioral analysis and scoring
- Automated clinical report generation
- Longitudinal trend analysis and predictive modeling
- Integration with existing research and clinical workflows
- HIPAA-compliant data security and privacy protection
Investment in Future Innovation
The NeuroSense AI development initiative represents Halberd's strategic commitment to AI-powered healthcare innovation. The Company plans additional platform expansions including human clinical applications, consumer wellness monitoring, and advanced predictive analytics capabilities.
"This is just the beginning," emphasized Hartman. "NeuroSense AI will establish our foundation in behavioral intelligence, but we see applications extending far beyond TBI research into general brain health, aging, and cognitive wellness monitoring."
To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
For more information, please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About NeuroSense AI
NeuroSense AI Corp. is an 89%-owned subsidiary of Halberd Corporation. NeuroSense AI is a revolutionary behavioral intelligence platform in development that combines advanced artificial intelligence with multi-modal sensor technology to transform neurological research and assessment.
The platform integrates ultrasonic vocalization analysis, micro-movement tracking, and social behavior monitoring through Claude AI-powered interpretation to provide unprecedented insights into brain health and recovery patterns. Initially designed for preclinical TBI research in animal models, NeuroSense AI Corp's cloud-native architecture enables scalable deployment from individual research labs to large multi-site clinical trials, with future applications extending to human clinical assessment and brain health monitoring.
The platform represents the first commercial application of AI-driven behavioral signal fusion technology, positioning Halberd Corporation and its partners at the forefront of next-generation neurological research capabilities.
About Halberd Corporation.
Halberd Corporation (OTC: HALB) is a technology holding company focused on developing breakthrough solutions for healthcare and medical applications. The Company's portfolio includes innovative approaches to disease treatment, diagnostic technologies, and AI-powered healthcare platforms. Halberd is committed to improving human health outcomes through advanced technology development and strategic partnerships with leading research institutions.
Safe Harbor Notice
This press release contains forward-looking statements regarding Halberd Corporation's business prospects and its NeuroSense AI platform. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
